ArticleMetabolites2022
Plasma Metabolite Signature Classifies Male LRRK2 Parkinson's Disease Patients.
Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Current Advancements in Untargeted Metabolomics Analysis and Testing Driven by Machine Learning: Prospects for Artificial Intelligence in Patient-Centric Healthcare Transformation.Applied biochemistry and biotechnology · 2026Review
- Causal Effects Between Neurodegenerative Diseases, Metabolites, and Brain Volume.Current Alzheimer research · 2026Article
- Metabolic modeling links gut microbiota to metabolic markers of Parkinson's disease.Gut microbes · 2025Article
- Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025Review
- Identification of metabolites reproducibly associated with Parkinson's Disease via meta-analysis and computational modelling.NPJ Parkinson's disease · 2024Article
- Multi-omics integration of scRNA-seq time series data predicts new intervention points for Parkinson's disease.Scientific reports · 2024Article
- Olaris Global Panel (OGP): A Highly Accurate and Reproducible Triple Quadrupole Mass Spectrometry-Based Metabolomics Method for Clinical Biomarker Discovery.Metabolites · 2024Article
- NMR Precision Metabolomics: Dynamic Peak Sum Thresholding and Navigators for Highly Standardized and Reproducible Metabolite Profiling of Clinical Urine Samples.Metabolites · 2024Article
- Perspective: metabolomics has the potential to change the landscape of kidney transplantation diagnostics.Biomarkers in medicine · 2024Article
- Omics data integration suggests a potential idiopathic Parkinson's disease signature.Communications biology · 2023Article
- Biological Magnetic Resonance Data Bank.Nucleic acids research · 2023Article
- Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.NPJ Parkinson's disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease, causing loss of motor and nonmotor function. Diagnosis is based on clinical symptoms that do not develop until late in the disease progression, at which point the majority of the patients' dopaminergic neurons are already destroyed. While many PD cases are idiopathic, hereditable genetic risks have been identified, including mutations in the gene for LRRK2, a multidomain kinase with roles in autophagy, mitochondrial function, transcription, molecular structural integrity, the endo-lysosomal system, and the immune response. A definitive PD diagnosis can only be made post-mortem, and no noninvasive or blood-based disease biomarkers are currently available. Alterations in metabolites have been identified in PD patients, suggesting that metabolomics may hold promise for PD diagnostic tools. In this study, we sought to identify metabolic markers of PD in plasma. Using a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.